Administration of Aspirin as a Prophylaxis Agent Against Venous Thromboembolism Results in Lower Incidence of Periprosthetic Joint Infection.
Publication/Presentation Date
9-1-2015
Abstract
The efficacy and safety of aspirin (ASA) for prevention of venous thromboembolism (VTE) following total joint arthroplasty (TJA) have been demonstrated. Our hypothesis was that postoperative ASA compared to warfarin lowers the incidence of periprosthetic joint infection (PJI). Between January 2006 and December 2012, 1456 patients received ASA and 1700 patients received warfarin following primary TJA as standard VTE prophylaxis. Logistic regression was utilized to identify independent risk factors of PJI. Incidence of PJI was significantly lower at 0.4% in patients receiving ASA vs. 1.5% in patients receiving warfarin (P< 0.001). Warfarin and elevated BMI were independent risk factors for PJI following TJA (P< 0.05). Our research suggests that the use of ASA compared to warfarin for VTE prophylaxis reduces the risk of PJI following TJA.
Volume
30
Issue
9 Suppl
First Page
39
Last Page
41
ISSN
1532-8406
Published In/Presented At
Huang, R., Buckley, P. S., Scott, B., Parvizi, J., & Purtill, J. J. (2015). Administration of Aspirin as a Prophylaxis Agent Against Venous Thromboembolism Results in Lower Incidence of Periprosthetic Joint Infection. The Journal of arthroplasty, 30(9 Suppl), 39–41. https://doi.org/10.1016/j.arth.2015.07.001
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
26182982
Department(s)
Administration and Leadership
Document Type
Article